Skip Navigation

European Heart Journal 2001 22(17):1601-1612; doi:10.1053/euhj.2000.2570
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

J.G.F. Clelanda,f1, K. Thygesenb, B.F. Uretskyc, P. Armstrongd, J.D. Horowitze, B. Massief, M. Packerg, P.A. Poole-Wilsonh and L. Rydén on behalf of the ATLAS investigatorsi

a University of Hull, U.K.
b Aarhus University Hospital, Denmark
c University of Texas, Galveston, U.S.A.
d University of Alberta, Edmonton, Canada
e University of Adelaide, Adelaide, Australia
f University of California, San Francisco, U.S.A.
g Columbia University, New York, U.S.A.
h Imperial College School of Medicine, University of London, U.K.
i Karolinska Institutet, Stockholm, Sweden

revised December 4, 2000; accepted December 6, 2000

Abstract

Aims To determine the sequence of critical cardiovascular events in the progression of heart failure, and whether aetiology or high-dose vs low-dose lisinopril affected these pathways.

Methods and Results This was a post-hoc investigation of the ATLAS database, which comprised 3164 patients with chronic heart failure, randomized to low- (2·5–5·0mg.day–1) or high-dose (32·5–35·0mg.day–1) lisinopril, followed up for a median of 46 months. Two-thirds (64·3%) of patients had heart failure attributed to ischaemic heart disease. During the study, most patients (61·1%) had at least one cardiovascular hospitalization and 42·5% of all patients died: most deaths (88·2%) were cardiovascular. Nearly half (49·7%) of the cardiovascular deaths were considered sudden and 45·2% of cardiovascular deaths occurred as the first cardiovascular event. A third (30·2%) of deaths resulted from heart failure and were generally preceded by hospitalization, either for heart failure (85·5%), myocardial ischaemic events (21·7%) or arrhythmias (18·0%). Compared with low-dose, high-dose lisinopril was associated with a lower risk of death or hospitalization for any reason (P=0·002) and death or hospitalization with worsening heart failure (P<0·001). High-dose lisinopril delayed the time to all-cause mortality and hospitalization for chronic heart failure by 7·1 months.

Conclusions Vascular and arrhythmic events may not only be important precipitants of sudden death, but were also seen to contribute to the progression of heart failure. A reduction in vascular events, as well as benefits on ventricular remodelling, could account for the decrease in death or hospitalization with high-dose lisinopril.

Key Words: Heart failure, lisinopril, ischaemia, arrhythymia, progression, critical events pathways

f1 Correspondence: Dr John G. F. Cleland, Department of Cardiology, Castle Hill Hospital, Castle Road, University of Hull, Kingston upon Hull, HU16 5JQ, U.K.

References

  1. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19:696–710
  2. Cleland JGF, Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: Remodelling, resetting, or sudden death? Br Heart J. 1994;72:S81–86
  3. Ghali JK, Kadakia S, Cooper R. Precipitating factors leading to decompensation of heart failure. Arch Intern Med. 1988;148:2013–2016
  4. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441
  5. Opasich C, Febo O, Ricardi PG. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 1996;78:354–357
  6. Cleland JGF, Gemmel I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Failure. 1999;1:229–241
  7. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J. 1997;18:41–51
  8. Konstam MA, Rousseau MF, Kronenberg MW. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431–438
  9. Rutherford JD, Pfeffer MA, Moye LA. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival And Ventricular Enlargement Trial. Circulation. 1994;90:1731–1738
  10. Sutton MSJ, Pfeffer MA, Moye L. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Baseline predictors and impact of long-term use of captopril: Information from the survival and ventricular enlargement (SAVE) trial. Circulation. 1997;96:3294–3299
  11. McDonagh TA, Morrison CE, Lawrence A. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–833
  12. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham study. J Am Coll Cardiol. 1993;22:6A–13A
  13. Senior R, Glenville B, Basu S. Dobutamine echocardiography and thallium-201 imaging predict functional improvement after revsacularisation in severe ischaemic left ventricular dysfunction. Br Heart J. 1995;74:358–364
  14. Rinaldi CA, Masani ND, Linka AZ, Hall RJ. Effect of repetitive episodes of exercise induced myocardial ischaemia on left ventricular function in patients with chronic stable angina: evidence for cumulative stunning or ischaemic preconditioning? Heart. 1999;81:404–411
  15. Cleland JGF, Pennell DJ, Murray GD. The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS). Eur J Heart Failure. 1999;1:191–196
  16. Kannel WB, Abbott RD. Incidence and prognosis of unrecognised myocardial infarction: An update on the Framingham Study. N Engl J Med. 1984;311:1144–1147
  17. Schwarz ER, Schoendube FA, Kostin S. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularisation. J Am Coll Cardiol. 1998;31:1018–1026
  18. Chen C, Ma L, Linfert DR. Myocardial cell death and apoptosis in hibernating myocardium. J Am Coll Cardiol. 1997;30:1407–1412
  19. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614–632
  20. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol. 1997;12:276–287
  21. Loh E, Sutton MS, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251–257
  22. Cleland JGF, Armstrong P, Horowitz JD. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. Eur J Heart Failure. 1999;1:73–79
  23. Packer M, Poole-Wilson PA, Armstrong PW. Comparative effects of low doses and high doses of the angiotensin converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:1–7
  24. Uretsky B, Armstrong PW, Cleland JGF. Ischemia as a ‘trigger’ for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: results from the ATLAS trial (Abstr). Circulation. 1998;98:I-199
  25. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Failure. 1999;1:41–45
  26. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79:909–913
  27. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425
  28. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;31:749–753
  29. Jones CG, Cleland JGF. Meeting report—the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Failure. 1999;1:425–431
  30. Unverferth DV, Magorien RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with non-ischemic congestive cardiomyopathy. Am Heart J. 1983;105:1476–1479
  31. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation following acute myocardial infarction. Circulation. 1999;100:376–380
  32. Deedwania PC, Singh BN, Ellenbogen K. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation. 1998;98:2574–2579
  33. Torp-Pedersen C, Moller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–865
  34. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet. 1998;352:S19–28
  35. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–1393
  36. Narang R, Cleland JGF, Erhardt L. Mode of death in chronic heart failure—a request and proposition for more accurate classification. Eur Heart J. 1996;17:1390–1403
  37. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler DS, Rajakangas A, Pajak A. Myocardial infarction and coronary deaths in the World Health Organisation MONICA project. Circulation. 1994;90:583–612
  38. N Engl J Med. 1997;337:1576–1583
  39. Moss AJ, Hall WJ, Cannom DS. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940
  40. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569–1575
  41. N Engl J Med. 2000;342:145–153
  42. Yusuf S, Pepine CJ, Garces C. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173–1178

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
S. Setoguchi, A. Nohria, J. A. Rassen, L. W. Stevenson, and S. Schneeweiss
Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure
Can. Med. Assoc. J., March 17, 2009; 180(6): 611 - 616.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. D. Flaherty, J. J. Bax, L. De Luca, J. S. Rossi, C. J. Davidson, G. Filippatos, P. P. Liu, M. A. Konstam, B. Greenberg, M. R. Mehra, et al.
Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment.
J. Am. Coll. Cardiol., January 20, 2009; 53(3): 254 - 263.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
J. G. Ray, C. M. Norris, J. A. Udell, R. T. Tsuyuki, F. A. McAlister, M. L. Knudtson, and W. A. Ghali
Lipid-Lowering Therapy and Outcomes in Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 27 - 35.
[Abstract] [PDF]

Home page
 Eur J Heart FailHome page
V. Rizzello, D. Poldermans, E. Biagini, A. F.L. Schinkel, E. Boersma, A. Elhendy, F. B. Sozzi, A. Maat, J. R.T.C. Roelandt, and J. J. Bax
Benefits of coronary revascularisation in diabetic and non-diabetic patients with ischaemic cardiomyopathy: Role of myocardial viability
Eur J Heart Fail, May 1, 2006; 8(3): 314 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. K.A. Witte, N. P. Nikitin, A. C. Parker, S. von Haehling, H.-D. Volk, S. D. Anker, A. L. Clark, and J. G.F. Cleland
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure
Eur. Heart J., November 1, 2005; 26(21): 2238 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. A. Masoudi, P. Wolfe, E. P. Havranek, S. S. Rathore, J. M. Foody, and H. M. Krumholz
Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease: National Prescription Patterns and Relationship With Outcomes
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 955 - 962.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J.G.F. Cleland, N. Freemantle, S.G. Ball, R.S. Bonser, P. Camici, S. Chattopadhyay, D. Dutka, J. Eastaugh, J. Hampton, S. Large, et al.
The heart failure revascularisation trial (HEART): rationale, design and methodology
Eur J Heart Fail, June 1, 2003; 5(3): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Zhang, L. J. Bloem, L. Yu, T. B. Estridge, P. W. Iversen, C. E. McDonald, J. P. Schrementi, X. Wang, C. J. Vlahos, and J. Wang
Protein kinase C {beta}II activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes
Cardiovasc Res, January 1, 2003; 57(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. R.J. Mitchell, P. A.R. Spurrell, H. Ahmet, M. Higson, and N. Sulke
Reversal of tachycardiomyopathy by the atrial defibrillator
Eur J Heart Fail, August 1, 2002; 4(4): 485 - 488.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
H. Krum and J. J. McMurray
Statins and chronic heart failure: do we need a large-scale outcome trial?
J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1567 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
S Orn and K Dickstein
How do heart failure patients die?
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D59 - D65.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
S.G. Ball
Why patients with heart failure die
Eur. Heart J., September 1, 2001; 22(17): 1523 - 1524.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?